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Abstract
Background: Ovarian cancer remains the leading cause of death from gynaecological malignancy. More than 60%
of the patients are presenting the disease in stage III or IV. In spite of combination of chemotherapy and surgery
the prognosis stays poor for therapy regimen.
Methods: The leaves of a plant endemic to Australia, Calomeria amaranthoides, were extracted and then
fractionated by column chromatography. In vitro cytotoxicity tests were performed with fractions of the plant
extract and later with an isolated compound on ovarian cancer cell lines, as well as normal fibroblasts at
concentrations of 1-100 μg/mL (crude extract) and 1-10 μg/mL (compound). Cytotoxicity was measured after 24,
48 and 72 hours by using a non-fluorescent substrate, Alamar blue.
In vivo cytotoxicity was tested on ascites, developed in the abdomen of nude mice after inoculation with human
OVCAR3 cells intraperitoneally. The rate of change in abdomen size for the mice was determined by linear
regression and statistically evaluated for significance by the unpaired t test.
Results: Two compounds were isolated by chromatographic fractionation and identified by
1H-NMR,
13C-NMR and
mass spectrometry analyses, EPD, an a-methylene sesquiterpene lactone of the eremophilanolide subtype, and
EPA, an a-methylene carboxylic acid.
Cytotoxicity of EPD for normal fibroblasts at all time points IC50 was greater than 10 μg/mL, whereas, for OVCAR3
cells at 48 hours IC50 was 5.3 μg/mL (95% confidence interval 4.3 to 6.5 μg/mL).
Both, the crude plant extract as well as EPD killed the cancer cells at a final concentration of 10 μg/mL and 5 μg/
mL respectively, while in normal cells only 20% cell killing effect was observed. EPA had no cytotoxic effects.
Changes in abdomen size for control versus Cisplatin treated mice were significantly different, P = 0.023, as were
control versus EPD treated mice, P = 0.025, whereas, EPD versus Cisplatin treated mice were not significantly
different, P = 0.13.
Conclusions: For the first time both crude plant extract from Calomeria amaranthoides and EPD have been shown
to have potent anti-cancer effects against ovarian cancer.
Background
Calomeria amaranthoides, described both by Ventenat
and Smith in 1804 [1,2] as Humea elegans belonging to
the genus Haeckeria in the tribe of Inuleae was grown
in France and England from seeds originating from the
Blue Mountains, New South Wales (NSW) in Australia.
The plant is of a monotypic genus, endemic to NSW
and Victoria, Australia [3].
In 2004 the genus Haeckeria was reassessed by Orch-
ard as C. amaranthoides and since then C. amar-
anthoides belongs to the genus Calomeria of the family
Asteraceae (Compositae) [4]. As a biennial plant it can
grow to more than three metres high, with flowers as
waving plume bushes and wrinkly leaves with an aro-
matic scent. It is also called incense plant.
The plant family of Asteraceae are known for their
natural products. One type includes sesquiterpene lac-
tones (SL) which to date is of great interest for their
potential as anti-cancer agents as reviewed by Heinrich
et al. and Zhang et al. [5,6].
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women and remains the leading cause of death from
gynaecological malignancy in many countries, in spite of
chemotherapy with Platinum derivates and/or Taxol
after surgery. Of the malignant epithelial tumors (>90%
of all ovarian cancers), the serous papillary variants
form the largest subgroup [7,8]. Due to its dismal prog-
nosis there is an urgent need for new treatment strategy
for ovarian cancer.
For the first time we have studied C. amaranthoides
for its possible anti-tumor activity. An SL (EPD) and a
structurally related sesquiterpene (EPA) have been
found, extracted and purified. Among them EPD has
shown in vitro and in vivo (mice) high toxicity in ovar-
ian cancers.
Methods
A voucher specimen of Calomeria amaranthoides,c o l -
lected near Old Bell’s Line of Road, Mount Tomah
NSW 2758, Australia, is held in the John Ray Herbar-
ium, University of Sydney, Collection number: Silvester
110118-01.
Leaves of C. amaranthoides, gathered in the Blue
Mountains (Mount Tomah, NSW, Australia) were air-
dried while protected from sunlight.
Fractionation of extracts by column chromatography
Dried plant material (350 g), cut in small pieces was
soaked in chloroform (CHCl3)a tr o o mt e m p e r a t u r e .
After 24-48 hours a crude extract of the leaves was
removed and evaporated under reduced pressure (21.3
grams, 6.0%). The residue, re-dissolved in CHCl3 (30
mL) was applied to a column (21 cm × 5 cm i.d.) filled
with Silicagel (Lichroprep Si 60, particle size 15-25 μm;
Merck, Germany). Elution was carried out with a step-
wise gradient consisting of hexane:dioxane, 98:2 (v/v
400 mL); hexane:chloroform:dioxane, 88:10:2 (v/v 600
mL); hexane:chloroform:dioxane:ethyl acetate:2-propa-
nol, 80:10:2:6:1, (v/v 600 mL) and hexane:chloroform:
acetone:methanol, 56:20:16:8, (v/v 400 mL). A total of
157 fractions (10 mL each) were collected and combined
into groups based on HPLC analysis. The combined
group of fractions showing the highest toxicity towards
ovarian cancer cells was further fractionated by short
column vacuum chromatography.
High-performance liquid chromatography (HPLC)
HPLC analyses were carried out using the Akta purifier
(Amersham Pharmacia Biotech, Sweden) with a HPLC-
column (150 mm × 4.6 mm i.d. plus pre-column; Grace,
The Netherlands), filled with HS Silica (particle size
3 μm), UV detection at 214 nm, 254 nm and 280 nm.
Ten μL of the fractionated extract was injected, after
dilution to 100 μL with eluent A: hexane (99.5 mL)-
dioxane (0.5 mL). The first 10 minutes the column was
eluted at a flow rate of 0.5 mL/min with eluent A, fol-
lowed by 30 minutes with eluent B: hexane (85 mL)-
diethyl ether (10 mL)-ethanol (5 mL).
1H-NMR and
13C-NMR analyses
1H-NMR and
13C-NMR spectroscopy was performed on
those plant fractions with clear cytotoxicity effects.
1H-
NMR,
13C-NMR and Correlation Spectroscopy (COSY)
were performed using a Varian Gemini 300 MHz instru-
ment (Palo Alto, CA, USA). The spectra were measured
in parts per million (ppm) and were referenced to tetra-
methylsilane (TMS = 0 ppm).
Electrospray ionisation in positive and negative mode
(ESI) mass spectrometry analyses were performed using
a TSQ 7000 Liquid Chromatography Mass Spectrometer
( L C - M S / M S ;T h e r m o ,S a nJ o s e ,C A ,U S A ) ,e q u i p p e d
with Xcalibur data acquisition and processing software.
Short-Column Vacuum Chromatography (SCVC) was
performed using a column packed with TLC-grade silica
gel H60 (Merck, Darmstadt, Germany)) and applying a
step-wise gradient of solvents with increasing polarity.
Substances were detected by TLC performed on silica
gel coated TLC plates (H60 F254, Merck, Germany) and
by
1H-NMR spectroscopy. Structures of purified
compounds were determined by mass spectrometry and
1H-NMR and
13C-NMR spectroscopy.
Graphs and Statistics
Graphing and statistical evaluations were carried out
with GraphPad Prism 5 for Windows.
Cell lines and cell cultures
Cells used in the assays were five ovarian cell lines (JV,
JG, JC, JoN, NF), which were earlier established [9,10],
two cell lines OVCAR3 and SKOV3 from the American
Type Culture Collection (ATCC) as well as epithelial
cells from the ovary (serous papillary cystadenomas) [11]
and human dermal fibroblasts primary cultures [12].
In vitro cytotoxicity tests with different fractions of C.
amaranthoides
In vitro cytotoxicity tests were performed using a non-
fluorescent substrate, Alamar blue (BioSource Invitro-
gen, UK), as described by Pagé et al. [13]. Ovary cells
(1 × 10
4 or 5 × 10
4)w e r es e e d e di n2 4 - w e l l sp l a t e s
(Costar, USA) and grown in RPMI-1640, supplemented
with 6 mM L-glutamine, 10% fetal calf serum (FCS)
(Gibco, Invitrogen, UK) and penicillin (100 units/mL)
and streptomycin (100 μg/mL), while normal fibroblasts
were grown in Dulbecco’s modified Eagle medium
(DMEM), also supplemented with L-glutamine and FCS.
The cultures were maintained in a humidified atmo-
sphere of 5% CO2 at 37°C.
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treated with the different dried fractions of the plant
extract, redissolved in dimethyl sulfoxide (DMSO) and
added at final concentrations of 1, 10 and 100 μg/mL.
The control cultures had 0.02% (1 μg/mL) 0.2% (10 μg/
mL) and 2% (100 μg/mL) DMSO added to the medium.
In 2 mL medium/well 10% Alamar blue was added and
100 μl of the supernatants of the 24-well plates after 24,
48 and 72 hrs incubations were pipetted into 96-well
plates (Costar, USA). Cell viability was measured with a
96-well plate reader (Molecular Devices Ltd, UK). In a
later stage, after identifying fractions with high cytotoxic
effects, the final concentrations of extracts tested ranged
from 1-10 μg/mL, with final concentrations of 0.02 up
to 0.2% DMSO.
In vivo pilot experiment
An in vivo pilot experiment was performed with 20
BALB/c nude mice (Charles River Laboratories, France).
In order to mimic advanced ovarian cancer the mice
were injected intraperitoneally (i.p.) with 10
7 OVCAR3
cells (ATCC) into the abdominal cavity to form ascites.
Three groups of mice were examined: 6 control mice
(no treatment), 6 mice treated with Cisplatin and 6 mice
treated with EPD after ascites had formed. Cells of
ascites of two mice were frozen and stored for future
experiments. To study reduction of the swollen abdo-
men 5 mg/kg Platosin (Cisplatin, Pharma Chemie, The
Netherlands) and the isolated compound EPD at a final
concentration of 20 mg/kg were administered i.p.
Results
Fractionation of extracts by column chromatography
In total 157 fractions were sampled and, based on HPLC
analyses, divided into four groups of combined fractions
(fractions: 1-6, 60-70, 90-100 and 120-130) and then
tested in vitro against ovarian cancer cell lines and nor-
mal cells. Group 2 (fractions: 60-70) showed the stron-
gest cytotoxicity, killing all ovarian cancer cells at 10 μg/
mL but not at 1 μg/mL. Other fractions did not show
significant activities. This second group of fractions
60-70 (1.30 g, 0.37% yield from crude extract) was
further fractionated by normal-phase short-column
vacuum chromatography on silica gel H (column dimen-
sions 18 mm × 65 mm i.d.), eluted with stepwise solvent
gradients of hexane: dichloromethane, 1:1 v/v (100 mL
and 50 mL); dichloromethane (2 × 50 mL); dichloro-
methane: ethyl acetate, 4:1 v/v (2 × 50 mL); dichloro-
methane: ethyl acetate, 1:1 v/v (2 × 50 mL); ethyl
acetate (2 × 50 mL). From each fraction (12 in total)
solvent was evaporated under reduced pressure and the
residue was weighed.
Bioassays with ovarian cancer cells indicated fraction 4
(309 mg, 0.09% of the dried plant; out of the twelve
fractions, see above) as the fraction with most of the
cytotoxicity and its main chemical constituent was iden-
tified as EPD. A second main non-cytotoxic constituent,
present mostly in Fractions 7 to 9 was identified as EPA
(137 mg, 91% purity by NMR and MS analyses).
Again, fractionation was applied to fraction 4
(enriched in EPD) using normal-phase short-column
vacuum chromatography (silica gel H; column dimen-
sions 18 mm × 65 mm i.d.), eluting with stepwise sol-
vent gradients of hexane:dichloromethane, 2:1 v/v (100
mL); hexane: dichloromethane, 1:1 v/v (2 × 50 mL); hex-
ane:dichloromethane, 1:2 v/v (2 × 50 mL); dichloro-
methane (2 × 50 mL); dichloromethane: ethyl acetate
4:1 (2 × 50 mL); dichloromethane: ethyl acetate, 1:1 v/v
(2 × 50 mL) to give the main chemical constituent,
identified as an SL, EPD (93 mg, 90% purity by NMR
and MS analyses) and containing lipids and waxes (10%
by NMR analyses).
A small sample of freshly dried leaves (1.63 g) was
extracted with dichloromethane (100 mL), filtered and
the dichloromethane removed under reduced pressure
leaving a dark green residue (62.6 mg, yield 3.9%).
Quantitative
1H-NMR analysis of a CDCl3 solution
s h o w e dE P D4 4 % ,E P A3 1 %a n dac o m p l e xm i x t u r eo f
unidentified constituents 25%.
A small sample of dried leaves (10.31 g), that had been
stored in the dark under ambient conditions for
3.5 years was extracted with CHCl3 (100 mL, 48 hours)
filtered and the CHCl3 removed under reduced pressure
leaving a dark green-brown residue (0.62 g, yield 6.0%).
Quantitative
1H-NMR analysis of a CDCl3 solution
showed that EPD and EPA were almost completely
absent and a very complex mixture of unidentified con-
stituents made up the bulk of the material.
1H-NMR and
13C-NMR analyses
Eremophila-1(10)-11(13)-dien-12,8b-olide (EPD)
(3aa,4aa,5a,9aa)-3a,4,4a,5,6,7,9,9a-octahydro-4a,5-
dimethyl-3-methylenenaphtho[2,3-b]furan-2(3H)-2-one
C15H20O2 colourless liquid;
1H-NMR (CDCl3): δ0.92
(s, H-14), 0.93 (d, J4,15 = 6.8 Hz, H-15), 1.50 (m, H-3),
1.60 (m, H-4), 1.70 (m, H-6), 2.03 (m, H-2), 2.30 (m, H-
9), 2.58 (dd, J9,9’ = 12.6 Hz, J8,9’ = 7.7 Hz, H-9’), 2.92 (m,
H-7), 4.53 (dt, J7,8 = 9.6 Hz, J8,9 = 7.4 Hz, H-8), 5.48 (br
t, J1,2 = 3.4 Hz, H-1), 5.59 (d, J13,13’ =2 . 2H z ,H - 1 3 ’),
6.23 (d, J13,13’ = 2.2 Hz, H-13);
13C-NMR (CDCl3):
δ16.08, 20.59, 25.03, 26.72, 34.69, 34.91, 36.63, 37.01,
38.73, 79.00, 121.82, 124.57, 138.32, 139.36, 170.65. Posi-
tive ion ESI-MS [M+Na]
+ 255 (100), [M+H]
+ 233 (65).
Xanthanodien or EPD is an a-methylene SL [14].
Eremophila-1(10),11(13)-dien-12-oic acid (EPA)
C15H22O2 colourless liquid;
1H-NMR (CDCl3): δ0.85 (d,
J4,15 = 6.4 Hz, H-15), 0.91 (s, H-14), 1.45 (m, H-6), 1.50
(m, H-4), 1.55 (m, H-3), 1.60 (m, H-8), 1.85 (m, H-9),
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Page 3 of 62.01 (m, H-2), 2.40 (m, H-9’), 2.55 (m, H-7), 5.38 (br t,
J1,2 = 3.4 Hz, H-1), 5.66 (br s, H-13’), 6.29 (br s, H-13);
13C-NMR (CDCl3): δ16.08, 20.59, 25.03, 26.72, 34.69,
34.91, 36.63, 37.01, 38.73, 79.00, 121.82, 124.57, 138.32,
139.36, 170.65. Negative ion ESI-MS [M-H]
- 233 (100)
EPA, is an a-methylene carboxylic acid [15].
The remaining impurities in the purified sample of
EPD and EPA (Figures 1A and 1B) were identified as
waxes and lipids. No other sesquiterpenoid substances
of similar structure to EPD and EPA were detected.
In vitro cytotoxicity tests
Cell viability of normal skin fibroblasts and of cells of
the ovarian cell line JC treated with the crude plant
extract for 24, 48 and 72 hours at final concentrations
of 1, 10 and 100 μg/mL was as follows:
The screening test for the fibroblasts with doses of 1,
10 and 100 μg/mL measured for 1 μg/mL: after 24
hours showed cell viability of 104%; after 48 hours 97%;
and after 72 hours 98%; for 10 μg/ml: after 24 hours cell
viability showed 100%; after 48 hours 96%; and after 72
hours 80%; and for 100 μg/mL: after 24 hours cell viabi-
lity showed 98%; after 48 hours 83%; and after 72 hours
65%. At all time points (24, 48 and 72 hours) IC50 was
greater than 100 μg/mL.
The screening test for the JC cells with doses of 1, 10
and 100 μg/mL measured for 1 μg/mL: after 24 hours
showed cell viability of 98%; after 48 hours 97%; and
after 72 hours 70%; for 10 μg/mL: after 24 hours cell
viability showed 85%; after 48 hours 84%; and after
72 hours 21%; for 100 μg/mL: after 24 hours cell viabi-
lity showed 77%; after 48 hours 84%; and after 72 hours
8%. At the time points 24 and 48 hours IC50 was greater
than 100 μg/mL and at 72 hours IC50 was 2.5 μg/mL
(95% confidence interval (C.I.) 0.22 to 28 μg/mL).
A similar type of biological assay was performed with
the purified compound EPD at final concentrations of 1,
5a n d1 0μg/mL for 24, 48 and 72 hours (Table 1). Per-
cent of cell reduction for normal fibroblasts at 72 hours
at the highest dose (10 μg/mL) was approximately 30%,
while IC 50 was greater than 10 μg/mL. Screening tests
for OVCAR3 and SKOV3 cells showed that more than
50% and 80% of cells were killed at doses of 5 and
10 μg/mL, respectively.
In vivo pilot experiment
Control mice only injected with the OVCAR3 cells, were
killed when the ascites became a burden. EPD (at final
concentration of 20 mg/kg b.w.) was administered i.p.
twice/week for six weeks and Cisplatin (at final concen-
tration of 5 mg/kg b.w.) was administered i.p. during
4 weeks, once/week. In general a similar cytotoxic effect
was observed between EPD and Cisplatin on the
OVCAR3 cells. However, mice treated with EPD could
be kept for a much longer period of time than those
mice treated with Cisplatin, for the latter the mice had
lost weight significantly and had to be sacrificed after
the fourth week. Moreover, following EPD treatment for
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Figure 1 Chemical structures. A. Chemical structure of an a-methylene sesquiterpene lactone, EPD. B. Chemical structure of an a-methylene
carboxylic acid, EPA.
Table 1 Cell viability with EPD treatment of normal
fibroblasts, OVCAR3 and SKOV3 cancer cells (average (AV)
and standard deviation (SD))
% cell viability: average and standard deviation
EPD Conc 24 hours 48 hours 72 hours
μg/mL AV SD AV SD AV SD
Normal fibroblasts
1 102 2.5 107 3.9 105 3.3
5 105 6.3 108 1.6 72 2.1
10 101 10.1 112 1.8 47 4.6
OVCAR3
1 96 5.1 101 7.4 109 29.2
5 87 6.7 67 4.5 50 14.4
10 70 7.4 23 0.9 21 6.4
SKOV3
1 103 5.0 123 8.2 119 6.0
5 102 4.0 96 18.2 69 16.5
10 86 11.6 31 36.0 23 1.8
IC50 for OVCAR3 at 24 hours was 13 μg/mL (95% C.I. 10 to 18 μg/mL), at 48
hours 6.4 μg/mL (95% C.I. 5.3 to 7.8 μg/mL) and at 72 hours 5.3 μg/mL (95%
C.I. 4.3 to 6.5 μg/mL).
IC50 for SKOV3 at 24 hours was 16 μg/mL (95% C.I. 9.4 to 27 μg/mL), at 48
hours 8.4 μg/mL (95% C.I. 6.7 to 11 μg/mL) and at 72 hours 6.5 μg/mL (95%
C.I. 5.2 to 8.3 μg/mL).
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to see if the reduced abdomen would stay of normal
size. Two mice kept their normal size abdomen,
whereas, after 6 weeks the abdomen of the third mouse
started to increase in size (Table 2).
T h er a t eo fc h a n g ei na b d o m e ns i z ef o rt h em i c ew a s
determined by linear regression (Figure 2) and statisti-
cally evaluated for significance by the unpaired t test.
Control versus Cisplatin treated mice were significantly
different, P = 0.023, as were control versus EPD treated
mice, P = 0.025, whereas, EPD versus Cisplatin treated
mice were not significantly different, P = 0.13.
Discussion
The chemical constituents composition of aerial parts of
C. amaranthoides have been examined once before by
Zdero et al. [16]. None of the constituents reported by
them were identified in the C. amaranthoides described
in this study. The three constituents reported [16] are
isomeric with the two major constituents reported in
this study, EDP and EPA. The different constituents
reported previously may be due to incomplete isolation
and analyses or possibly the result of variation in consti-
tuent profiles of plant phenotypes. Another possible
explanation is degradation on storage. Our studies have
shown that freshly dried plant material is necessary as
dried plant material stored for over three years was
found to yield less than one-tenth of the normal yield of
EDP and EPA.
For the first time the anti-cancer activity of C. amar-
anthoides has been examined. Two major sesquiterpenes
with the eremophilanolide structure sub-type were
identified by
1H-NMR and
13C-NMR and by mass spec-
trometry and by comparison with published
1H-NMR
partial spectra as eremophila-1(10)-11(13)-dien-12,8b-
olide (EPD or Xanthanodien) and eremophila-1(10),11
(13)-dien-12-oic acid (EPA) [14,15]. Belonging to the
family of Asteraceae, this family has contributed a large
number of natural products including SL’s. The alpha-
methylene gamma-lactone ring is responsible for their
bioactivity. Various SL’s have demonstrated their anti-
cancer capability in in vitro cell culture and by preven-
tion of metastasis in in vivo animal models [6]. Thus, it
is not surprising that C. amaranthoides extract can kill
cancer cells, given the fact that one of the two isolated
sesquiterpenes, EPD, shows high toxicity.
In 1972 a diastereoisomer of EPD, (3ab,4aa,5a,9ab)-
3a,4,4a,5,6,7,9,9a octahydro4a,5-dimethyl-3-methylene-
naphtho[2,3-b]furan-2(3H)-2-one, has been described as
“naphthofuranone” by the National Cancer Institute
(NCI) in their “in vivo“ anti-tumor screening data, test-
ing the drug against P388 Leukemia in CD2F1 mice,
however, no final conclusive results were reported [17].
An allergenic sesquiterpene lactone, Alantolactone,
found in “Elfdock” Inula helenium has been shown to
be toxic to leukocytes. Although with the same molecu-
lar weight and molecular formula as EPD it belongs to
the eudesmanolide structure sub-type [18]. This SL has
a different chemical structure from EPD, with different
positions of one methyl and one double bond.
In the present study, EPA, the other sesquiterpene iso-
lated and identified, did not show cytotoxic effects on
the ovarian cancer at concentrations up to 10 μg/mL of
purified compound.
Besides the cytotoxic effects of the crude extract of C.
amaranthoides with clear effects at 10 μg/mL (cell
reduction >80%), the isolated biologically active com-
pound EPD has been shown to have high cytotoxicity
(>50%) for ovarian cancer cells at lower concentrations
of 5 μg/mL (72 hours) and increased (> 60%) with a
dose of 10 μg/mL (at 48 hours; Table 1). Interestingly,
both the crude plant extract and EPD did show only a
slight cytotoxic effect (20%-30%) on normal fibroblasts
in vitro at a concentration of 10 μg/mL (at 72 hours).
The in vivo pilot experiment with BALB/c nude mice
(Table 2, Figure 2) did show that both EPD and Cispla-
tin reduced the size of the abdomen. The difference,
however, was that mice treated with Cisplatin were in
poor condition and became wasted compared with the
EPD treated mice.
Ovarian cancer has a poor prognosis. With more than
60% of the patients presenting the disease in stage III or
IV, combination chemotherapy with Platinum and Taxol
after cytoreductive surgery gives the most tolerated stan-
dard regimen [19,20].
Table 2 Average abdomen size and standard deviation of
BALB/c nude mice
Average abdomen size and standard deviation (cm)
Control cisplatin EPD
Days AV SD AV SD AV SD
1 2.1 0.173 2.567 0.115 2.333 0.115
7 2.4 0.173
8 2.333 0.153 2.525 0.33
12 2.367 0.231
14 2.5 0.258
16 2.767 0.153
19 2.475 0.222 2.267 0.058
21 3 0.346 2.5 0.183
26 3.1 0.141 2.1 0.1 1.967 0.208
33 2 0
36 2.267 0.058
61 2.467 0.289
63 2.533 0.321
68 2.7 0.794
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management of ovarian cancer there is still need for
more novel treatments.
Conclusion
The compound EPD has shown unique cytotoxicity
effects on both in vitro (ovarian cancer cell lines) as well
as in vivo (mice). Interestingly, it had low cytotoxic
effects on normal cells.
More studies in vivo are required to verify the
mechanisms and mode of action of EPD, and to further
validate the potential of EPD as an anti-cancer drug in
ovarian cancer and other types of cancer.
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